CIK 0001133416
- Non-accelerated filer
- Smaller reporting company
GALECTIN THERAPEUTICS INC
Sign in to watch- Ticker
- GALT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- Operating
- EIN
- 043562325
- Phone
- +1 678-620-3186
- Business address
- 4960 PEACHTREE INDUSTRIAL BOULEVARD, SUITE 240, NORCROSS, GA, 30071
- Former names
- PRO PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-16 | LEWIS JOEL President and CEO | Grant or award · Stock option (right to buy) | +91,000 | 91,000 | ||
| 2026-01-16 | LEWIS JOEL President and CEO | Grant or award · Stock option (right to buy) 10b5-1 | +84,000 | 65,000 | ||
| 2026-01-16 | LEWIS JOEL President and CEO | Grant or award · Restricted Stock Unit 10b5-1 | +120,000 | 100,000 | ||
| 2026-01-06 | LEWIS JOEL President and CEO | Sale 10b5-1 | −37,698 | $3.58 | $135K | 832,592 |
| 2026-01-05 | LEWIS JOEL President and CEO | Other disposition 10b5-1 | −56,332 | $3.88 | $219K | 776,260 |
| 2026-01-05 | LEWIS JOEL President and CEO | Sale 10b5-1 | −27,731 | $3.91 | $108K | 870,290 |
| 2026-01-02 | LEWIS JOEL President and CEO | Exercise or conversion 10b5-1 | +84,000 | 916,592 | ||
| 2026-01-02 | LEWIS JOEL President and CEO | Sale 10b5-1 | −18,571 | $4.20 | $78K | 898,021 |
| 2026-01-02 | LEWIS JOEL President and CEO | Exercise or conversion · Restricted Stock Unit 10b5-1 | −84,000 | 0 | ||
| 2025-12-17 | LEWIS JOEL President and CEO | Exercise or conversion 10b5-1 | +7,829 | $2.86 | $22K | 840,421 |
| 2025-12-17 | LEWIS JOEL President and CEO | Sale 10b5-1 | −7,829 | $7.06 | $55K | 832,592 |
| 2025-12-17 | LEWIS JOEL President and CEO | Exercise or conversion · Stock option (right to buy) 10b5-1 | −7,829 | 32,171 | ||
| 2025-11-18 | LEWIS JOEL President and CEO | Exercise or conversion 10b5-1 | +6,783 | $2.39 | $16K | 839,375 |
| 2025-11-18 | LEWIS JOEL President and CEO | Sale 10b5-1 | −6,783 | $6.15 | $42K | 832,592 |
| 2025-11-18 | LEWIS JOEL President and CEO | Exercise or conversion · Stock option (right to buy) 10b5-1 | −6,783 | 0 | ||
| 2025-11-17 | LEWIS JOEL President and CEO | Exercise or conversion 10b5-1 | +15,680 | $2.39 | $37K | 848,272 |
| 2025-11-17 | LEWIS JOEL President and CEO | Sale 10b5-1 | −15,680 | $6.04 | $95K | 832,592 |
| 2025-11-17 | LEWIS JOEL President and CEO | Exercise or conversion · Stock option (right to buy) 10b5-1 | −15,680 | 6,783 | ||
| 2025-11-10 | LEWIS JOEL President and CEO | Exercise or conversion 10b5-1 | +1,867 | $2.39 | $4K | 834,459 |
| 2025-11-10 | LEWIS JOEL President and CEO | Sale 10b5-1 | −1,867 | $6.03 | $11K | 832,592 |
Page 1 of 5 · 99 trades